BSX insider trading
NYSE HealthcareBOSTON SCIENTIFIC CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About BOSTON SCIENTIFIC CORP
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Company website: www.bostonscientific.com
BSX insider activity at a glance
FilingIQ has scored 3,076 insider transactions for BSX since Feb 24, 2014. The most recent filing in our index is dated Aug 11, 2026.
Across the full history, 19 open-market purchases
and 454 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BSX insider trades is 66.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BSX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading BSX
13F funds holding BSX
Politicians who have traded BSX
Frequently asked
- How many insider trades does FilingIQ track for BSX?
- FilingIQ tracks 3,076 Form 4 insider transactions for BSX (BOSTON SCIENTIFIC CORP), covering filings from Feb 24, 2014 onwards. 13 of those were filed in the last 90 days.
- Are BSX insiders net buyers or net sellers?
- Across the full Form 4 history for BSX, 19 transactions (1%) were open-market purchases and 454 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BSX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is BSX in?
- BOSTON SCIENTIFIC CORP (BSX) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $71.46B.
Methodology & sources
Every BSX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.